journal article·2017-01-02Open access

Modulation of microRNAs expression in hematopoietic stem cells treated with sodium butyrate in inducing fetal hemoglobin expression

Behnoosh Tayebi, Fatemeh Abrishami, Shaban Alizadeh, Neda Minayi, Mozhdeh Mohammadian, Masoud Soleimani, Ali Dehghanifard, Hossein Atwan, Monireh Ajami, Mansoureh Ajami

Abstract

Context Inherited hemoglobin diseases are the most common single-gene disorders. Induction of fetal hemoglobin in beta hemoglobin disorders compensate for abnormal chain and ameliorate the clinical complications. Sodium butyrate is used conventionally for fetal hemoglobin induction; it can be replaced by safer therapeutic tools like microRNAs, small non-coding RNAs that control number of epigenetic mechanisms. Objective In this study, we compared the changes in the microRNAs of differentiated erythroid cells between control and sodium butyrate treated groups. The objective is to find significant association between these changes and gamma chain up regulation. Materials and methods First, CD133+ hematopoietic stem cells were isolated from cord blood by magnetic cell sorting (MACS) technique. After proliferation, the cells were differentiated to erythroid lineage in culture medium by EPO, SCF, and IL3. Meanwhile, the test group was treated with sodium butyrate. Then, gamma chain upregulation was verified by qPCR technique. Finally, microRNA profiling was performed through microarray assay and some of them confirmed by qPCR. Result Results demonstrated that gamma chain was 5.9-fold upregulated in the treated group. Significant changes were observed at 76 microRNAs, in which 20 were up-regulated and 56 were down-regulated. Discussion Five of these microRNAs including U101, hsa-miR-4726-5p, hsa-miR7109 5p, hsa-miR3663, and hsa-miR940 had significant changes in expression and volume. Conclusion In conclusion, it can be assumed that sodium butyrate can up-regulate gamma chain gene, and change miRNAs expression. These results can be profitable in future studies to find therapeutic goal suitable for such disorders.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Hemoglobinopathies and Related Disorders · MicroRNA in disease regulation · Prenatal Screening and Diagnostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Faculty of Medicine, Qaem Hospital, Mashhad University of Medical Sciences and Health Care Services, Mashhad, Iran;

Hematology Department, School of Allied Medical, Tehran University of Medical Sciences, Tehran, Iran;

Amol Faculty of Paramedical Sciences, Mazandaran University of Medical Sciences, Sari, Iran;

Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;

Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran;

Taleghani Bone Marrow Transplantation Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran;

Immunology Department, Iran University of Medical Science, Tehran, Iran

References (41)

Show source-provided references
1. Ahmadvand M · Int J Hematol Oncol Stem Cell Res · 2014 · 8 · 9
2. Ahmadvand M · Genetics · 2011 · 9 · 2373
3. Alijani S · Avicenna J Med Biotechnol · 2014 · 6 · 53
4. 10.1371/journal.pone.002283810.1371/journal.pone.0022838 ↗
5. 10.1182/blood-2005-05-211310.1182/blood-2005-05-2113 ↗
6. 10.5483/BMBRep.2009.42.8.49310.5483/BMBRep.2009.42.8.493 ↗
7. 10.1182/blood-2003-02-047810.1182/blood-2003-02-0478 ↗
8. 10.1128/MCB.00035-1510.1128/MCB.00035-15 ↗
9. 10.1182/blood.V74.6.1963.196310.1182/blood.V74.6.1963.1963 ↗
10. 10.1182/blood.V122.21.925.92510.1182/blood.V122.21.925.925 ↗
11. Dehghanifard A · Zahedan J Res Med Sci · 2012 · 14 · 29
12. Dehghanifard A · Genetics · 2011 · 9 · 2457
13. 10.1097/00062752-199502020-0000210.1097/00062752-199502020-00002 ↗
14. Fard AD · Int J Hematol Oncol Stem Cell Res · 2013 · 7 · 47
15. 10.1532/LH96.1200310.1532/LH96.12003 ↗
16. Fathallah H · ASH Educ Program · 2006 · 2006 · 58
17. 10.1182/blood.V82.7.2203.220310.1182/blood.V82.7.2203.2203 ↗
18. 10.3324/haematol.2009.01825910.3324/haematol.2009.018259 ↗
19. 10.1186/1750-1172-5-1110.1186/1750-1172-5-11 ↗
20. 10.1017/S146239940601065910.1017/S1462399406010659 ↗
21. 10.1016/S0301-472X(00)00555-510.1016/S0301-472X(00)00555-5 ↗
22. Minayi N · Int J Hematol Oncol Stem Cell Res · 2014 · 8 · 15
23. 10.1056/NEJM19880114318020710.1056/NEJM198801143180207 ↗
24. 10.1177/153537021559685910.1177/1535370215596859 ↗
25. Panja A · J Cytol Histol · 2015 · 6 · 360
26. Perrine S. · Thalassemia Rep · 2011 · 1 · e710.4081/thal.2011.s2.e7 ↗
27. 10.1182/blood.V74.1.454.45410.1182/blood.V74.1.454.454 ↗
28. 10.3928/00904481-20080501-1010.3928/00904481-20080501-10 ↗
29. 10.1056/NEJM19930114328020210.1056/NEJM199301143280202 ↗
30. 10.1016/S0140-6736(10)61029-X10.1016/S0140-6736(10)61029-X ↗
31. 10.1056/NEJMra05043610.1056/NEJMra050436 ↗
32. Sankaran VG. · ASH Educ Program · 2011 · 2011 · 459
33. 10.1073/pnas.101838410810.1073/pnas.1018384108 ↗
34. 10.1111/j.1365-2141.2005.05768.x10.1111/j.1365-2141.2005.05768.x ↗
35. 10.1016/j.exphem.2004.11.00710.1016/j.exphem.2004.11.007 ↗
36. 10.1097/00005792-200109000-0000710.1097/00005792-200109000-00007 ↗
37. 10.1101/gad.139980610.1101/gad.1399806 ↗
38. 10.1182/blood-2011-07-36874610.1182/blood-2011-07-368746 ↗
39. 10.1182/blood-2004-02-045410.1182/blood-2004-02-0454 ↗
40. 10.1038/264247a010.1038/264247a0 ↗
41. 10.3109/21691401.2014.98280410.3109/21691401.2014.982804 ↗